123 related articles for article (PubMed ID: 12669244)
1. Functional characterization of CTL against gp100 altered peptide ligands.
Dionne SO; Smith MH; Marincola FM; Lake DF
Cancer Immunol Immunother; 2003 Apr; 52(4):199-206. PubMed ID: 12669244
[TBL] [Abstract][Full Text] [Related]
2. Improved induction of melanoma-reactive CTL with peptides from the melanoma antigen gp100 modified at HLA-A*0201-binding residues.
Parkhurst MR; Salgaller ML; Southwood S; Robbins PF; Sette A; Rosenberg SA; Kawakami Y
J Immunol; 1996 Sep; 157(6):2539-48. PubMed ID: 8805655
[TBL] [Abstract][Full Text] [Related]
3. Identification of new melanoma epitopes on melanosomal proteins recognized by tumor infiltrating T lymphocytes restricted by HLA-A1, -A2, and -A3 alleles.
Kawakami Y; Robbins PF; Wang X; Tupesis JP; Parkhurst MR; Kang X; Sakaguchi K; Appella E; Rosenberg SA
J Immunol; 1998 Dec; 161(12):6985-92. PubMed ID: 9862734
[TBL] [Abstract][Full Text] [Related]
4. Antimelanoma activity of CTL generated from peripheral blood mononuclear cells after stimulation with autologous dendritic cells pulsed with melanoma gp100 peptide G209-2M is correlated to TCR avidity.
Yang S; Linette GP; Longerich S; Haluska FG
J Immunol; 2002 Jul; 169(1):531-9. PubMed ID: 12077285
[TBL] [Abstract][Full Text] [Related]
5. Shared epitopes for HLA-A3-restricted melanoma-reactive human CTL include a naturally processed epitope from Pmel-17/gp100.
Skipper JC; Kittlesen DJ; Hendrickson RC; Deacon DD; Harthun NL; Wagner SN; Hunt DF; Engelhard VH; Slingluff CL
J Immunol; 1996 Dec; 157(11):5027-33. PubMed ID: 8943411
[TBL] [Abstract][Full Text] [Related]
6. Stimulation of tumor-reactive T lymphocytes using mixtures of synthetic peptides derived from tumor-associated antigens with diverse MHC binding affinities.
Riley JP; Rosenberg SA; Parkhurst MR
J Immunol Methods; 2003 May; 276(1-2):103-19. PubMed ID: 12738363
[TBL] [Abstract][Full Text] [Related]
7. Her-2/ neu altered peptide ligand-induced CTL responses: implications for peptides with increased HLA affinity and T-cell-receptor interaction.
Dionne SO; Myers CE; Smith MH; Lake DF
Cancer Immunol Immunother; 2004 Apr; 53(4):307-14. PubMed ID: 14605764
[TBL] [Abstract][Full Text] [Related]
8. HLA-A2.1/K(b) transgenic murine dendritic cells transduced with an adenovirus encoding human gp100 process the same A2.1-restricted peptide epitopes as human antigen-presenting cells and elicit A2.1-restricted peptide-specific CTL.
Yang S; Linette GP; Longerich S; Roberts BL; Haluska FG
Cell Immunol; 2000 Aug; 204(1):29-37. PubMed ID: 11006015
[TBL] [Abstract][Full Text] [Related]
9. Immunization of patients with melanoma peptide vaccines: immunologic assessment using the ELISPOT assay.
Pass HA; Schwarz SL; Wunderlich JR; Rosenberg SA
Cancer J Sci Am; 1998; 4(5):316-23. PubMed ID: 9815296
[TBL] [Abstract][Full Text] [Related]
10. Novel approach to the characterization of melanoma associated-peptide-specific CTL lines from Japanese metastatic melanoma patients.
Akiyama Y; Maruyama K; Tai S; Takikawa M; Ohshita C; Yamamoto A; Yamazaki N; Kiyohara Y; Yamaguchi K
Int J Oncol; 2008 Sep; 33(3):433-41. PubMed ID: 18695871
[TBL] [Abstract][Full Text] [Related]
11. Recognition of multiple epitopes in the human melanoma antigen gp100 by tumor-infiltrating T lymphocytes associated with in vivo tumor regression.
Kawakami Y; Eliyahu S; Jennings C; Sakaguchi K; Kang X; Southwood S; Robbins PF; Sette A; Appella E; Rosenberg SA
J Immunol; 1995 Apr; 154(8):3961-8. PubMed ID: 7706734
[TBL] [Abstract][Full Text] [Related]
12. Identification of gp100-derived, melanoma-specific cytotoxic T-lymphocyte epitopes restricted by HLA-A3 supertype molecules by primary in vitro immunization with peptide-pulsed dendritic cells.
Kawashima I; Tsai V; Southwood S; Takesako K; Celis E; Sette A
Int J Cancer; 1998 Nov; 78(4):518-24. PubMed ID: 9797143
[TBL] [Abstract][Full Text] [Related]
13. Identification of five new HLA-B*3501-restricted epitopes derived from common melanoma-associated antigens, spontaneously recognized by tumor-infiltrating lymphocytes.
Benlalam H; Linard B; Guilloux Y; Moreau-Aubry A; Derré L; Diez E; Dreno B; Jotereau F; Labarrière N
J Immunol; 2003 Dec; 171(11):6283-9. PubMed ID: 14634146
[TBL] [Abstract][Full Text] [Related]
14. Peptide-specific CTL in tumor infiltrating lymphocytes from metastatic melanomas expressing MART-1/Melan-A, gp100 and Tyrosinase genes: a study in an unselected group of HLA-A2.1-positive patients.
Spagnoli GC; Schaefer C; Willimann TE; Kocher T; Amoroso A; Juretic A; Zuber M; Luscher U; Harder F; Heberer M
Int J Cancer; 1995 Oct; 64(5):309-15. PubMed ID: 7591302
[TBL] [Abstract][Full Text] [Related]
15. Immunogenicity of the ALLAVGATK (gp100[17-25]) peptide in HLA-A3.1 melanoma patients.
Castelli C; Mazzocchi A; Rini F; Tarsini P; Rivoltini L; Maio M; Gallino G; Belli F; Parmiani G
Eur J Immunol; 1998 Apr; 28(4):1143-54. PubMed ID: 9565353
[TBL] [Abstract][Full Text] [Related]
16. Recognition of multiple epitopes in the human melanoma antigen gp100 by peripheral blood lymphocytes stimulated in vitro with synthetic peptides.
Salgaller ML; Afshar A; Marincola FM; Rivoltini L; Kawakami Y; Rosenberg SA
Cancer Res; 1995 Nov; 55(21):4972-9. PubMed ID: 7585538
[TBL] [Abstract][Full Text] [Related]
17. Proteasomal cleavage does not determine immunogenicity of gp100-derived peptides gp100 209-217 and gp100 209-217T210M.
Nagorsen D; Servis C; Lévy N; Provenzano M; Dudley ME; Marincola FM; Lévy F
Cancer Immunol Immunother; 2004 Sep; 53(9):817-24. PubMed ID: 15133631
[TBL] [Abstract][Full Text] [Related]
18. Dendritic cells infected with a vaccinia vector carrying the human gp100 gene simultaneously present multiple specificities and elicit high-affinity T cells reactive to multiple epitopes and restricted by HLA-A2 and -A3.
Yang S; Kittlesen D; Slingluff CL; Vervaert CE; Seigler HF; Darrow TL
J Immunol; 2000 Apr; 164(8):4204-11. PubMed ID: 10754316
[TBL] [Abstract][Full Text] [Related]
19. Peptide fine specificity of anti-glycoprotein 100 CTL is preserved following transfer of engineered TCR alpha beta genes into primary human T lymphocytes.
Schaft N; Willemsen RA; de Vries J; Lankiewicz B; Essers BW; Gratama JW; Figdor CG; Bolhuis RL; Debets R; Adema GJ
J Immunol; 2003 Feb; 170(4):2186-94. PubMed ID: 12574392
[TBL] [Abstract][Full Text] [Related]
20. T-cell clones from melanoma patients immunized against an anchor-modified gp100 peptide display discordant effector phenotypes.
Dudley ME; Ngo LT; Westwood J; Wunderlich JR; Rosenberg SA
Cancer J; 2000; 6(2):69-77. PubMed ID: 11069222
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]